A股異動 | 富瀚微(300613.SZ)漲7.7% 擬收購眸芯科技32.43%股權
格隆匯1月27日丨富瀚微(300613.SZ)漲7.7%,報127.99元,總市值102億元。富瀚微昨日公吿,公司擬向拉薩君祺等以支付現金的方式收購眸芯科技32.43%股權,本次交易完成後,公司持有的眸芯科技股權比例將由18.57%變更為51%,眸芯科技將成為公司的控股子公司。眸芯科技是一家專注於超大規模智能音視頻處理器SoC芯片以及相關解決方案開發的公司,在超大規模SoC芯片設計,高速外設接口及模擬IP設計,低功耗設計,高清視頻智能處理、壓縮和存儲,高清顯示等方面具備豐富的經驗。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.